A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of a Unani Formulation in Kalaf (Melasma).

Kalaf (Melasma) is a common acquired disorder of hyperpigmentation characterized by irregular light to dark brown macules on the sun exposed area of the face. The prevalence of melasma ranges from 8.8% to 40%.It affects all age population but mostly common in 21-44 years age group.Melasma affects all races especially Hispanics, Asians, Africans, Arab and mostly affects person with darker skin type.  Exact cause of melasma is unknown, but various risk factors that play an important role to aggravate melasma i.e. uncontrolled sun exposure, pregnancy, hormonal influences, darker phenotype, genetic factors. It produces considerable impact on the patient’s quality of life. It further produces psychological upset in the form of low self-esteem, nervousness, irritation, depression and anxiety. Melasma is a curable disease but it requires long term treatment. It has been observed that recurrence after cessation of treatment is a most common problem. Conventional therapy such as application of hydroquinone produces various side effects like dermatitis, post inflammatory pigmentation. Nowadays cosmetics having metal which are very dangerous to the health are being used. Hence it is felt that there is a need to search for safe and effective treatment for melasma.